Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 9, Number 9, September 2017, pages 802-808

Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study

Figures

Figure 1.
Figure 1. (a) The change in HbA1c levels from the baseline to the final visit with alogliptin therapy in all individuals. (b) The mean change ± standard deviation (SD) in HbA1c levels from the baseline to the final visit with alogliptin therapy. *Statistical significance. Final visit: mean 3.5 years from baseline.
Figure 2.
Figure 2. (a) The change in plasma glucose (PG) levels from the baseline to the final visit with alogliptin therapy in all individuals. (b) The mean change ± SD in PG levels from the baseline to the final visit with alogliptin therapy. Final visit: mean 3.5 years from baseline.
Figure 3.
Figure 3. The change in HbA1c levels from the baseline to the final visit with alogliptin therapy in a subgroup patients who either did not change all of their anti-diabetic drugs or the dose of sulfonylureas (SUs) was decreased, or the SUs were changed to a lower strength repaglinide (n = 32). *Statistical significance. Final visit: mean 3.5 years from baseline.
Figure 4.
Figure 4. (a) The change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline to the final visit with alogliptin therapy in all patients who had LDL-C levels measured (n = 37). (b) The change of high-density lipoprotein cholesterol (HDL-C) levels from the baseline to the final visit with alogliptin therapy in all patients who had HDL-C levels measured (n = 36). (c) The change in LDL-C levels from the baseline to the final visit with alogliptin therapy in a subgroup patients who did not take either statins, fibrates, or pioglitazone, or who had taken one or more of these drugs but the dose was not changed during the observation period (n = 27). (d) The change in HDL-C levels from the baseline to the final visit with alogliptin therapy in a subgroup patients who did not take either statins, fibrates or pioglitazone, or who had taken one or more of these drugs but the dose was not changed during the observation period (n = 26). *Statistical significance. Final visit: mean 3.5 years from baseline.

Table

Table 1. Clinical Features at Baseline in Patients With Type 2 Diabetes
 
Data are expressed as mean ± SD. BMI: body mass index; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; diabetic therapy: the number of the patients with respective diabetic therapies; S: sulfonylurea; M: metformin; A: α glucosidase inhibitor; P: pioglitazone.
No. (male/female)39 (20/19)
Age (years)69.3 ± 8.6
Mean duration of alogliptin therapy (months)42.8 ± 2.2
BMI (kg/m2)24.4 ± 3.9
FPG (mg/dL)164.6 ± 34.7
HbA1c (%)7.8 ± 0.6
Diabetic therapy
  S/M/A/SM/SMA/SMAP/SP/SPA/none12/4/1/8/5/2/2/1/4
  Statins7
  Fibrates3